Molecular Panel Evaluation for Diagnosis of Infections of the Central Nervosous System
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 170 people enrolled
- Started
- 17 Apr 2024
- Ended
- 31 Dec 2024
- Type of study
- Observational
- Treatments tested
- QIAstat-Dx®Meningitis/Encephalite Panel
- Record updated
- 18 December 2025
Who can take part
- Sex
- Women and men
Show the full registry criteria (8)Hide the full registry criteria
Who can take part
- 170 samples of CSF positive for virus and/or bacteria
- Samples stored at -80°C, less than 5 years
- Samples with a volume of at least 800μL
Who cannot take part
- Samples of a different matrix than CSF
- Samples stored at room temperature
- Samples for which diagnostic test results are not available
- Samples with a volume of less than 800μL
- Samples already thawed and refrozen
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Infections involving the central nervous system (CNS), such as meningitis/encephalitis (ME), are serious clinical conditions associated with high morbidity and mortality rates, as well as significant long-term consequences. ME can be caused by a wide variety of pathogenic agents. Clinical symptoms may vary and it has been shown that early identification of the pathogens causing ME allows for timely and appropriate treatment, thus reducing permanent neurological damage. The multiparameter panel "QIAstat-Dx®Meningitis/Encephalitis" can detect in one hour on a sample of 15 bacterial, viral and fungal pathogens. In the diagnostic routine, Real-time PCR takes an average of 3 hours and culture examination 2 days. In addition, compared to other comparable rapid molecular systems, the "QIAstat-Dx" platform has the ability to generate a cycle-related threshold value (Ct) for the targets detected. This value may have a correlation with the viral load and thus provide in a short time not only the result of positivity, but also an indication of the amount of virus present. Other commercially available multiparameter molecular tests provide only qualitative data.
The group in the trial
- Positive Samples
Positive samples for viruses or bacteria typical of meningitis/encephalitis
Treatment: QIAstat-Dx®Meningitis/Encephalite Panel
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Multiparametric Molecular Panel Evaluation "QIAstatDxMeningitis/Encephalitis" for Diagnosis of Infections of the Central Nervosous System
- Record updated
- 18 December 2025